PACTR202408653853505尚未招募2 期
Safety and immunogenicity of a second generation Shigella bioconjugate vaccine: a phase II randomized, controlled, and blinded study in 9-month-old infants
immaTech Biologics AG0 个研究点目标入组 110 人开始时间: 2024年4月30日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1 Month(s) 至 23 Month(s)（—）
- 性别
- All
入选标准
- •1. Female or male aged 9 months (± 1 month) old at the time of the first vaccination.
- •2. Born full-term (i.e., after a gestation period of 37 to less than 42 full weeks).
- •3. Healthy by medical history, laboratory findings and physical examination before entering into the study (Participants with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.
- •4. Seronegative for HIV, hepatitis B and C (as per screening laboratory tests).
- •5. Resident of Siaya County during the whole trial period.
- •6. Previously completed routine primary vaccinations (6,10 and 14 weeks or thereabouts) to the best knowledge of the participant’s parent/guardian. This information will be abstracted from the maternal and child health booklet. All the participant’s parent/guardian will be requested to carry this booklet whenever they visit the clinic.
- •7. Signed/thumb printed informed consent, in accordance with local practice, provided by participants’ parents or guardian who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •8. Demonstrated comprehension (by the parent/guardian) of the protocol procedures through passing a written/verbal comprehension test with a score of 80% or higher (at least 10 out of 12 questions).
排除标准
- •1. Any clinically significant deviation from the normal range in biochemistry or hematological blood tests.
- •2. Suspected or known hypersensitivity (including allergy) to any of the vaccine components or to previous vaccine, or to medicinal products or medical equipment whose use is foreseen in this study
- •3. Clinical conditions representing a contraindication to intramuscular vaccination and blood draws
- •4. Any confirmed or suspected immunosuppressive or immune-deficient condition.
- •5. Systemic administration of corticosteroids (PO/IV/IM): prednisone =20 mg/day, or equivalent for more than 14 consecutive days from birth within 90 days prior to informed consent. Inhaled except for doses > 800 mg/day and topical steroids are allowed.
- •6. Administration of antineoplastic or radiotherapy from birth / within 90 days prior to informed consent. Participants may be on chronic or as needed medications if, in the opinion of the site principal investigator or appropriate sub-investigator, they pose no additional risk to participant safety or assessment of reactogenicity and immunogenicity and do not indicate a worsening of medical diagnosis or condition
- •7. Known exposure to Shigella during lifetime of the study participant
- •8. Concurrently participating in another clinical study, or participation in the preceding month, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).
- •9. Acute illness with or without fever is a temporary exclusion criterium. Positive malaria test is a temporary exclusion criterion.
- •10. History of any malignancy of lymphoproliferative disorder
- •11. Parent/guardian known to be part of study personnel or being a close family member to the personnel conducting this study.
- •12. Previous history of significant persistent neutropenia, or drug related Neutropenia
- •13. Weight-for-age Z score less than -3SD.
- •14. History of any chronic or p
研究者
相似试验
未知
不适用
PHASE 11 STUDY OF THE SAFETY AND IMMUNOGENICITY OF TWO NOVEL H1N1 INFLUENZA VACCINES COMPARED TO PLACEBO AND COMMERCIALLY AVAILABLE TRIVALENT INFLUENZA VACCINE (T1V) IN HEALTHY ADULTS 18-64 YEARS IN LIMA, PERPER-037-12VaxInnate Corporation,
已完成
1 期
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months.Prophylaxis against infections diseases: Diphtheria, Tetanus, B. pertussis, H. influenzae type b and hepatitis B.RPCEC00000103Center for Genetic Engineering and Biotechnology (CIGB).624
尚未招募
1 期
ABDALA Clinical StudyCOVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000346Center for Genetic Engineering and Biotechnology (CIGB), in Havana
尚未招募
1 期
Safety and immunogenicity of VCN7-T in infants of 2 and 3 months. Phase I/II.Pneumococcal diseaseHealthy VolunteersPneumococcal InfectionsStreptococcal InfectionsGram-Positive Bacterial InfectionsRPCEC00000243Finlay Institute Vaccine880
招募中
不适用
Wetenschappelijk onderzoek naar de veiligheid van HPV-DNA vaccinatie en reactie van hetafweersysteem op deze vaccinatie bij patiënten met een HPV16-positieve afwijking aan deschaamlippen.NL-OMON29038KI-AV